Added to YB: 2026-09-18
Pitch date: 2026-09-16
ADAG [neutral]
Adagene Inc.
Author Info
No bio for this author
Company Info
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.
Market Cap
$199.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.30
P/E
-7.52
EV/Sales
10.13
Sector
Biotechnology
Category
special_situation
Biotech Conference Coverage Week 2 Day 2 part 2 - Adagene Inc.
ADAG (quick overview): Adagene’s thesis is that masked CTLA-4 antibody ADG-126 could provide a potentially safer, more combinable immunotherapy backbone, but randomized proof remains essential. Management reported roughly 15%-36% confirmed response rates in a small early dataset and under 10% adverse-event discontinuation across more than 60 MSSCRC patients. Incyte and Sanofi collaborations suggest outside combination interest; ADAG has a 76 M&A Score and 68 Growth Score, while the decisive Phase 2 readout is expected in 1H 2027.
Read full article (2 min)